Literature DB >> 3708037

Stress-induced immobility in rats with cholinergic supersensitivity.

D H Overstreet, D S Janowsky, J C Gillin, P J Shiromani, E L Sutin.   

Abstract

Immobility during forced swimming or after mild footshock (1 mA for 2 sec) was observed in five groups of rats. The Flinders Sensitive Line (FSL) of rats, known to be more sensitive to cholinergic agonists, exhibited the greatest degree of immobility in the forced swim test. Rats chronically treated with, and subsequently withdrawn from, either scopolamine (2 mg/kg, once daily) or amitriptyline (10 mg/kg, once daily) were also significantly more immobile than either a control group treated chronically with isotonic saline or the Flinders Resistant Line (FRL) of rats in the forced swim test. Similar trends were observed for locomotor depression in the open field following exposure to footshock. Receptor binding studies indicated significantly greater concentrations of muscarinic acetylcholine receptors in the hippocampus of the scopolamine, and amitriptyline, withdrawn rats. These findings indicate that rats with increased cholinergic sensitivity are more sensitive to the immobility-inducing effects of mild stressors. Thus, they may prove to be useful models for studying the relationship between affective disorders and the cholinergic system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708037     DOI: 10.1016/0006-3223(86)90127-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  9 in total

Review 1.  Genetic and pharmacological models of cholinergic supersensitivity and affective disorders.

Authors:  D H Overstreet; R W Russell; A D Crocker; J C Gillin; D S Janowsky
Journal:  Experientia       Date:  1988-06-15

2.  Effect of imipramine in the "learned helplessness" model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine.

Authors:  M Geoffroy; J Scheel-Krüger; A V Christensen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression.

Authors:  D H Overstreet; O Pucilowski; A H Rezvani; D S Janowsky
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

Review 4.  Relevance of Rodent Models of Depression in Clinical Practice: Can We Overcome the Obstacles in Translational Neuropsychiatry?

Authors:  Johan Söderlund; Maria Lindskog
Journal:  Int J Neuropsychopharmacol       Date:  2018-07-01       Impact factor: 5.176

Review 5.  Animal Models of Depression: What Can They Teach Us about the Human Disease?

Authors:  Maria Becker; Albert Pinhasov; Asher Ornoy
Journal:  Diagnostics (Basel)       Date:  2021-01-14

Review 6.  Repurposing Cholinesterase Inhibitors as Antidepressants? Dose and Stress-Sensitivity May Be Critical to Opening Possibilities.

Authors:  Paul J Fitzgerald; Pho J Hale; Anjesh Ghimire; Brendon O Watson
Journal:  Front Behav Neurosci       Date:  2021-01-14       Impact factor: 3.558

7.  Hippocampal-Dependent Antidepressant Action of the H3 Receptor Antagonist Clobenpropit in a Rat Model of Depression.

Authors:  Teresa Femenía; Salvatore Magara; Caitlin M DuPont; Maria Lindskog
Journal:  Int J Neuropsychopharmacol       Date:  2015-03-11       Impact factor: 5.176

8.  The Drosophila ETV5 Homologue Ets96B: Molecular Link between Obesity and Bipolar Disorder.

Authors:  Michael J Williams; Anica Klockars; Anders Eriksson; Sarah Voisin; Rohit Dnyansagar; Lyle Wiemerslage; Anna Kasagiannis; Mehwish Akram; Sania Kheder; Valerie Ambrosi; Emilie Hallqvist; Robert Fredriksson; Helgi B Schiöth
Journal:  PLoS Genet       Date:  2016-06-09       Impact factor: 5.917

Review 9.  The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?

Authors:  Won Je Jeon; Brian Dean; Elizabeth Scarr; Andrew Gibbons
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.